A novel ring-substituted diindolylmethane, 1,1-bis[3′-(5- methoxyindolyl)]-1-(p-t-butylphenyl) methane, inhibits extracellular signal-regulated kinase activation and induces apoptosis in acute myelogenous leukemia

Cancer Research

Volumn 65, Issue 7, 2005, Pages 2890-2898

  Contractor, Rooha ^a   Samudio, Ismael J ^a   Estrov, Zeev ^a   Harris, David ^a   McCubrey, James A ^c   Safe, Stephen H ^b,d   Andreeff, Michael ^a   Konopleva, Marina ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c EAST CAROLINA UNIVERSITY   (United States)

^d TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1 BIS[3' (5 METHOXYINDOLYL)] 1 (4 TERT BUTYLPHENYL)METHANE; ANTILEUKEMIC AGENT; CASPASE; CASPASE 9; CYTOCHROME C; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PROTEIN BAX; PROTEIN BCL 2; RECEPTOR BLOCKING AGENT; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CLONOGENESIS; CONTROLLED STUDY; CYTOSOL; DRUG INHIBITION; DRUG SELECTIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL TOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SUBSTITUTION REACTION; TRANSACTIVATION;

ACUTE DISEASE; APOPTOSIS; CASPASES; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HL-60 CELLS; HUMANS; INDOLES; JURKAT CELLS; LEUKEMIA, MONOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MAP KINASE SIGNALING SYSTEM; PPAR GAMMA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; U937 CELLS;

EID: 16844370972     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3781     Document Type: Article

References (48)

1. Estey EH. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 2000;14:476-9.
2. Greenberg P, Advani R, Tallman M, et al. Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: randomized phase III trial (E2995). Blood 1999;94:383a.
3. Kolitz JE, George SL, Hurd D, et al. Parallel phase 1 trials of multi-drug resistance (MDR) modulation with PSC-833 (PSC) in untreated patients (pts) with acute myeloid leukemia (AML) <60 years old: preliminary results of CALGB 9621. Blood 1999;94:384a.
4. Traver D, Akashi K, Weissman IL, Lagasse E. Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Science 1998;9:47-57.
5. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 1999;68:383-424.
6. Schimmer AD, Pedersen IM, Kitada S, et al. Functional blocks in caspase activation pathways are common in leukemia and predict patient response to induction chemotherapy. Cancer Res 2003;63:1242-8.
7. Campos L, Rouault JP, Sabido O, et al. High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993;81:3091-6.
8. Kornblau SM, Thall PF, Estrov Z, et al. The prognostic impact of BCL-2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res 1999;5:1758-66.
9. Ito T, Deng X, Carr B, May WS. Bcl-2 phosphorylation required for anti-apoptosis function. J Biol Chem 1997;272:11671-3.
10. Deng X, Ruvolo P, Carr B, May WS. Survival function of ERK 1/2 as IL-3-activated staurosporine-resistant Bcl2 kinases. Proc Natl Acad Sci U S A 2000;97:1578-83.
11. McDougal A, Gupta MS, Morrow D, Ramamoorthy K, Lee JE, Safe SH. Methyl-substituted diindolylmethanes as inhibitors of estrogen-induced growth of T47D cells and mammary tumors in rats. Breast Cancer Res Treat 2001;66:147-57.
12. Hong C, Kim HA, Firestone GL, Bjeldanes LF. 3,3′-Diindolylmethane (DIM) induces a G(1) cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21 (WAF1/CIP1) expression. Carcinogenesis 2002;23:1297-305.
13. Nachshon-Kedmi M, Yannai S, Haj A, Fares FA. Indole-3-carbinol and 3,3′ -diindolylmethane induce apoptosis in human prostate cancer cells. Food Chem Toxicol 2003;41:745-52.
14. Bonnesen C, Eggleston IM, Hayes JD. Dietary indoles and isothiocyanates that are generated from cruciferous vegetables can both stimulate apoptosis and confer protection against DNA damage in human colon cell lines. Cancer Res 2001;61:6120-30.
15. Qin C, Morrow D, Stewart J, et al. A new class of peroxisome proliferator-activated receptor γ (PPARγ) agonists that inhibit growth of breast cancer cells: 1,1-bis(3′-indolyl)-1-(p-substituted phenyl) methanes. Mol Cancer Ther 2004;3:247-60.
16. Kucharova S, Farkas H. Hormone nuclear receptors and their ligands: role in programmed cell death. Endocr Regul 2002;36:37-60.
17. Elstner E, Müller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998;95:8806-11.
18. Yang WL, Frucht H. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis 2001;22:1379-83.
19. Konopleva M, Elstner E, McQueen T, et al. PPARγ and RXR ligands are potent inducers of differentiation and apoptosis in leukemias. Mol Cancer Ther 2004;3:1249-62.
20. Lee G, Elwood F, McNally J, et al. T0070907, a selective ligand for peroxisome proliferator-activated receptor γ, functions as an antagonist of biochemical and cellular activities. J Biol Chem 2002;277:19649-57.
21. Juo P, Kuo CJ, Yuan J, Blenis J. Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr Biol 1998;8:1001-8.
22. Huang Y, Ibrado AM, Reed JC, et al. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia 1997;11:253-7.
23. Kuida K, Haydar TF, Kuan CY, et al. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 1995;94:324-37.
24. Kuida K, Zheng TS, Na S, et al. Decreased apoptosis in the brain and lethality in CPP32-deficient mice. Nature 1996;384:368-72.
25. Hoyle PE, Moye PW, Steelman LS, et al. Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK kinase1-dependent mechanism. Leukemia 2000;14:642-56.
26. Evans RL, Poe BS, Goodrich DW. Nuclear localization is required for induction of apoptotic cell death by the Rb-associated p84N5 death domain protein. Oncogene 2004;21:4691-5.
27. Poot M, Pierce RH. Detection of changes in mitochondrial function during apoptosis by simultaneous staining with multiple fluorescent dyes and correlated multiparameter flow cytometry. Cytometry 1999;35:311-7.
28. Hong J, Samudio I, Liu S, Abdelrahim M, Safe S. Peroxisome proliferators activated receptor γ-dependent activation of p21 in PANC-28 pancreatic cancer cells involves sp1 and sp4 proteins. Endocrinology 2004;145:5774-85.
29. Chintharlapalli S, Smith R, Samudio I, Zhang W, Safe S. 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl) methanes induce peroxisome proliferator-activated receptor γ-mediated growth inhibition, transactivation and differentiation markers in colon cancer cells. Cancer Res 2004;64:5994-6001.
30. Wang JL, Liu D, Zhang ZJ, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A 2000;97:7124-9.
31. Zhao S, Konopleva M, Cabreira-Hansen M, et al. Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia 2004;18:267-75.
32. Forman BM, Chen J, Evans RM. The peroxisome-proliferator-activated receptors: ligands and activators. Ann N Y Acad Sci 1996;804:266-75.
33. Slee EA, Harte MT, Kluck RM. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol 1999;144:281-92.
34. Joza N, Susin SA, Daugas E, et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature 2001;410:549-54.
35. Van Loo G, Saelens X, Van Gurp M, MacFarlane M, Martin SJ, Vandenabeele P. The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death Differ 2002;9:1031-42.
36. Gross A, Jockel J, Wei MC, Korsmeyer SJ. Enforced dimerization of Bax results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J 1998;17:3978-85.
37. Xuefang C, Xingming D, Stratford M. Cleavage of Bax to p18 Bax accelerates stress-induced apoptosis, and a cathepsin-like protease may rapidly degrade p18 Bax. Blood 2003;102:2605-14.
38. Yeo JK, Cha SD, Cho CH, et al. Se-methylselenocysteine induced apoptosis through caspase activation and Bax cleavage mediated by calpain in SKOV-3 ovarian cancer cells. Cancer Lett 2002;182:83-92.
39. Yanase N, Ohshima K, Ikegami H, Mizuguchi J. Cytochrome c release, mitochondrial membrane depolarization, caspase-3 activation, and Bax-α cleavage during IFN-α-induced-apoptosis in Daudi B lymphoma cells. J Interferon Cytokine Res 2000;20:1121-9.
40. L. Nat Cell Biol 2001;3:173-82.
41. Konopleva M, Tsao T, Ruvolo P, et al. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood 2002,99:326-35.
42. Milella M, Estrov Z, Kornblau SM, et al. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood 2002;99:3461-4.
43. Fang X, Yu S, Eder A, et al. Regulation of Bad phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene 1999;18:6635-40.
44. Andreeff M, Jiang S, Zhang X, et al. Expression of Bcl-2 related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia 1999;13:1881-92.
45. Hu E, Kim JB, Sarraf P, Spiegelman BM. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPAR γ. Science 1996;274:2100-3.
46. 3-dependent signal transduction by phosphorylating human retinoid X receptor α. J Clin Invest 1999;103:1729-35.
47. Milella M, Kornblau SM, Estrov Z, et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 2001;108:851-9.
48. Milella M, Konopleva M, Tabe Y, et al. MEK blockade converts AML differentiating response to retinoic acid (RA) into extensive apoptosis. Blood 2003;102:2194a.